CY1118634T1 - Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6’-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3’η-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ενα σπασμολυτικο - Google Patents

Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6’-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3’η-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ενα σπασμολυτικο

Info

Publication number
CY1118634T1
CY1118634T1 CY20171100205T CY171100205T CY1118634T1 CY 1118634 T1 CY1118634 T1 CY 1118634T1 CY 20171100205 T CY20171100205 T CY 20171100205T CY 171100205 T CY171100205 T CY 171100205T CY 1118634 T1 CY1118634 T1 CY 1118634T1
Authority
CY
Cyprus
Prior art keywords
dimethyl
amine
phenyl
acid
pharmaceutical composition
Prior art date
Application number
CY20171100205T
Other languages
Greek (el)
English (en)
Inventor
Stefanie Frosch
Klaus Linz
Thomas Christoph
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1118634T1 publication Critical patent/CY1118634T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20171100205T 2012-05-18 2017-02-15 Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6’-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3’η-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ενα σπασμολυτικο CY1118634T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12003898 2012-05-18
EP13159330 2013-03-15
EP13723004.1A EP2852384B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant
PCT/EP2013/001471 WO2013170972A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant

Publications (1)

Publication Number Publication Date
CY1118634T1 true CY1118634T1 (el) 2017-07-12

Family

ID=48446244

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100205T CY1118634T1 (el) 2012-05-18 2017-02-15 Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6’-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3’η-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ενα σπασμολυτικο

Country Status (20)

Country Link
US (1) US9345689B2 (https=)
EP (1) EP2852384B1 (https=)
JP (1) JP6116679B2 (https=)
CN (1) CN104284656A (https=)
AU (1) AU2013262078B2 (https=)
CA (1) CA2873871A1 (https=)
CY (1) CY1118634T1 (https=)
DK (1) DK2852384T3 (https=)
EA (1) EA029767B1 (https=)
ES (1) ES2624220T3 (https=)
HR (1) HRP20170517T1 (https=)
HU (1) HUE031984T2 (https=)
IL (1) IL235654A (https=)
LT (1) LT2852384T (https=)
MX (1) MX353177B (https=)
PL (1) PL2852384T3 (https=)
PT (1) PT2852384T (https=)
RS (1) RS55905B1 (https=)
SI (1) SI2852384T1 (https=)
WO (1) WO2013170972A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
EP3419621A4 (en) * 2016-02-26 2019-10-30 The Johns Hopkins University PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
MA51978A (fr) * 2016-12-06 2021-01-20 Hesselink Jan Marius Keppel Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2006514934A (ja) 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド 疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
US20040222123A1 (en) * 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN1245379C (zh) 2003-10-30 2006-03-15 曹桂东 加巴喷丁的制法
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2008501778A (ja) 2004-06-09 2008-01-24 ファイザー・インク 疼痛の治療のためのレボキセチンの使用
GB0412878D0 (en) 2004-06-09 2004-07-14 Pfizer Ltd Use
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
JP2008106028A (ja) * 2006-10-26 2008-05-08 Boehringer Ingelheim Internatl Gmbh 慢性疼痛の治療におけるフリバンセリンの使用
US20080153874A1 (en) 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2008108639A1 (en) 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
EP1977744A1 (en) 2007-04-03 2008-10-08 Chemo Ibérica, S.A. Polymorphic Form alpha of (S)-Pregabalin and process for its preparation
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
WO2009146325A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
AU2011287952B2 (en) * 2010-08-04 2014-08-21 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane- 1,1'-pyrano[3,4,b]indol]-4-amine
WO2012016703A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR20130097173A (ko) * 2010-08-04 2013-09-02 그뤼넨탈 게엠베하 신경병증성 통증을 치료하기 위한 ６’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­４­페닐­４’，９’­디하이드로­３’Ｈ­스피로[사이클로헥산­１，１’­피라노[３，４，ｂ]인돌]­４­아민을 포함하는 약제학적 투여형

Also Published As

Publication number Publication date
EP2852384B1 (en) 2017-02-01
PT2852384T (pt) 2017-05-10
EA029767B1 (ru) 2018-05-31
PL2852384T3 (pl) 2017-09-29
CA2873871A1 (en) 2013-11-21
IL235654A0 (en) 2015-01-29
RS55905B1 (sr) 2017-09-29
CN104284656A (zh) 2015-01-14
US9345689B2 (en) 2016-05-24
ES2624220T3 (es) 2017-07-13
MX353177B (es) 2018-01-05
JP2015516452A (ja) 2015-06-11
MX2014013179A (es) 2015-01-19
AU2013262078B2 (en) 2017-10-26
WO2013170972A1 (en) 2013-11-21
EA201401271A1 (ru) 2015-05-29
EP2852384A1 (en) 2015-04-01
HK1204937A1 (en) 2015-12-11
AU2013262078A1 (en) 2015-01-22
HUE031984T2 (en) 2017-08-28
DK2852384T3 (en) 2017-05-08
SI2852384T1 (sl) 2017-04-26
JP6116679B2 (ja) 2017-04-19
HRP20170517T1 (hr) 2017-06-02
US20130317009A1 (en) 2013-11-28
LT2852384T (lt) 2017-04-25
IL235654A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
CY1118634T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6’-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3’η-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ενα σπασμολυτικο
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
UA99476C2 (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
GT201100127A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
EA201290032A1 (ru) Синтез и применение вилдаглиптина для получения лекарственных форм
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
CY1106873T1 (el) Συνθεση για φαρμακευτικη χρηση ή για χρηση ως συμπληρωμα διατροφης για την αντιμετωπιση τριχοπτωσης
CY1109775T1 (el) Κρυσταλλικες μορφες μιας διφαινυλικης ενωσης
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
EA200900900A1 (ru) Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение
EA201270087A1 (ru) Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
CY1118528T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια καταθλιψης και αγχους
BR112015012842A2 (pt) diazol lactamas
HRP20050386A2 (en) Daily melatonin dosing units
FR2920023B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
DK2094699T3 (da) Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
CY1119777T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6'-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και γκαμπαπεντινοειδες
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada